Kintara therapeutics announces correction to prior announcement regarding cvr issuance in connection with the proposed merger with tuhura biosciences expected to close on october 18, 2024

San diego , oct. 15, 2024 /prnewswire/ -- kintara therapeutics, inc. ("kintara") (nasdaq: ktra), a biopharmaceutical company focused on the development of new solid tumor cancer therapies, today announced a correction to the press release previously issued by kintara on october 14, 2024, regarding a record date for the issuance of the contingent value rights ("cvrs") to stockholders of kintara pursuant to the definitive merger agreement (the "merger agreement") with tuhura biosciences, inc. ("tuhura"). kintara announced today that the cvrs will not be issued to stockholders of record of kintara based on a record date of october 17, 2024, but rather will be issued stockholders of record of kintara immediately prior to the planned reverse stock split that will be consummated immediately prior to the proposed merger.
CVR Ratings Summary
CVR Quant Ranking